High plasma IL-6 affects both cancer specific outcomes (relapse and survival) and patient-centered outcomes as functional decline (performance status, decreased mobility, deficits in instrumental activities of daily living) [15,23,39,40,41,42]. This evidence concerns the gene IL6 and cancer.